Vir Biotechnology announced it has achieved the target enrollment of approximately 3,000 participants in the groundbreaking Phase 2 PENINSULA (PrevEntioN of IllNesS DUe to InfLuenza A trial evaluating VIR-2482 for the prevention of illness due to influenza A. PENINSULA is the first Phase 2 outpatient trial to evaluate the role of a monoclonal antibody in the prevention of influenza A illness. The first participant was dosed in October 2022 and initial trial data are expected in mid-2023. "We are experiencing the worst flu season in more than a decade, with at least 150,000 hospitalizations and 9,300 deaths from flu reported in the U.S. alone so far. These numbers emphasize the urgent need for additional preventive approaches against seasonal flu, especially for those at highest risk of hospitalization," said Phil Pang, M.D., Ph.D., executive vice president, chief medical officer and interim head of research at Vir Biotechnology. "The rapid enrollment of the PENINSULA trial is a significant milestone that brings us one step closer to addressing the critical gap in preventing flu illness among those at high risk of serious illness. We look forward to reviewing the initial data to better understand whether a single shot of VIR-2482 has the potential to provide protection for the entire flu season."
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on VIR:
- Vir Biotechnology Achieves Target Enrollment for Groundbreaking Phase 2 PENINSULA Trial Evaluating VIR-2482 for Prevention of Seasonal Influenza A
- Vir Biotechnology Ranked the Fastest-Growing Company in North America on the 2022 Deloitte Technology Fast 500™
- Vir Biotechnology Presents New Data Evaluating the Potential for VIR-2218 and VIR-3434 to Achieve a Functional Cure for Chronic Hepatitis B Virus (HBV) Infection
- Vir Biotechnology Announces Multiple Abstracts Highlighting New Hepatitis B Data Accepted for Presentation at AASLD’s The Liver Meeting® 2022